CHEK1 and ovarian neoplasm: Although our results do not elucidate whether CHEK1 acts more like an oncogene or suppressor in ovarian tumors, further investigation of its variants appears interesting in the context of potential targeted therapies with Prexasertib, a selective CHEK1 inhibitor.